Linked Data API

Show Search Form

Search Results

1132403
unstar this property registered interest false more like this
unstar this property date less than 2019-06-17more like thismore than 2019-06-17
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading Orkambi more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what contingency plans his Department has put in place in the event that Vertex declines NHS England’s latest offer for the supply of Orkambi. more like this
star this property tabling member constituency Birmingham, Selly Oak more like this
star this property tabling member printed
Steve McCabe more like this
star this property uin 265417 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer remove filter
star this property answer text <p>NHS England is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi, and Symkevi in advance of assessment by the National Institute for Health and Care Excellence (NICE), and expanded access to Kalydeco which is already funded on the National Health Service for certain patients.</p><p>The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to urge Vertex to accept NHS England’s generous offer, but we will explore other options to ensure patients can access treatments as soon as possible.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy remove filter
star this property grouped question UIN 265418 more like this
star this property question first answered
less than 2019-06-20T09:33:36.433Zmore like thismore than 2019-06-20T09:33:36.433Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
298
unstar this property label Biography information for Steve McCabe more like this
1132404
unstar this property registered interest false more like this
unstar this property date less than 2019-06-17more like thismore than 2019-06-17
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading Orkambi: Clinical Trials more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of launching a large scale clinical trial of the generic version of Orkambi. more like this
star this property tabling member constituency Birmingham, Selly Oak more like this
star this property tabling member printed
Steve McCabe more like this
star this property uin 265418 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer remove filter
star this property answer text <p>NHS England is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi, and Symkevi in advance of assessment by the National Institute for Health and Care Excellence (NICE), and expanded access to Kalydeco which is already funded on the National Health Service for certain patients.</p><p>The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to urge Vertex to accept NHS England’s generous offer, but we will explore other options to ensure patients can access treatments as soon as possible.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy remove filter
star this property grouped question UIN 265417 more like this
star this property question first answered
less than 2019-06-20T09:33:36.47Zmore like thismore than 2019-06-20T09:33:36.47Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
298
unstar this property label Biography information for Steve McCabe more like this
1132599
unstar this property registered interest false more like this
unstar this property date less than 2019-06-17more like thismore than 2019-06-17
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading Out-patients: Attendance more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the cost to the public purse of missed (a) GP and (b) hospital appointments. more like this
star this property tabling member constituency Tewkesbury more like this
star this property tabling member printed
Mr Laurence Robertson more like this
star this property uin 265416 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer remove filter
star this property answer text <p>Information surrounding the cost of missed general practitioner and hospital appointments is not collected or held centrally.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy remove filter
star this property question first answered
less than 2019-06-20T09:32:08.917Zmore like thismore than 2019-06-20T09:32:08.917Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
253
unstar this property label Biography information for Mr Laurence Robertson more like this
1131740
unstar this property registered interest false more like this
unstar this property date less than 2019-06-12more like thismore than 2019-06-12
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading National Institute for Health and Care Excellence more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, which topics have been identified for inclusion in the upcoming review of the appraisal methods used by NICE. more like this
star this property tabling member constituency Cambridge more like this
star this property tabling member printed
Daniel Zeichner more like this
star this property uin 263870 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer remove filter
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes used in the development of its technology appraisal and highly specialised technologies recommendations. NICE has now initiated the review of its technology appraisal and highly specialised technologies methods in line with the commitment made in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.</p><p> </p><p>The Voluntary Scheme states that industry and other relevant stakeholders will be active participants in the review, including inputting on scope, participating in working discussions, and providing views on recommendations. NICE’s updated methods guide will also be subject to a public consultation.</p><p> </p><p>NICE has established a working group, consisting of members from NICE, NHS England, the Department, patient organisations and the life sciences industry. The working group reports to a steering group, chaired by NICE and with members from NHS England, the Department, and an independent academic methodologist. The steering group will present its recommendations to NICE’s Senior Management Team, which in turn will report to the NICE Board. NICE approached patient groups with experience of NICE and its processes and methods. There are three patient group representatives on the working group with a wide range of experience, covering a range of topic areas, reflecting the programmes under review. Membership of the working group will be published in due course.</p><p> </p><p>NICE is now in the process of scoping the review of the methods for technology appraisal and highly specialised technologies evaluations with input from the working group and steering group. The scope of the review - a list of the aspects of NICE’s current methods that will be considered in the review - will be presented to the NICE Board in July. Additional detail and more information will be made available on the NICE website in due course. NICE anticipates being in a position to confirm the revised methods guide by the end of 2020, following public consultation.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy remove filter
star this property grouped question UIN
263871 more like this
263872 more like this
263873 more like this
263874 more like this
star this property question first answered
less than 2019-06-20T13:18:08.087Zmore like thismore than 2019-06-20T13:18:08.087Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4382
unstar this property label Biography information for Daniel Zeichner more like this
1131742
unstar this property registered interest false more like this
unstar this property date less than 2019-06-12more like thismore than 2019-06-12
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading National Institute for Health and Care Excellence more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what the timescale is for NICE's Methods review. more like this
star this property tabling member constituency Cambridge more like this
star this property tabling member printed
Daniel Zeichner more like this
star this property uin 263871 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer remove filter
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes used in the development of its technology appraisal and highly specialised technologies recommendations. NICE has now initiated the review of its technology appraisal and highly specialised technologies methods in line with the commitment made in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.</p><p> </p><p>The Voluntary Scheme states that industry and other relevant stakeholders will be active participants in the review, including inputting on scope, participating in working discussions, and providing views on recommendations. NICE’s updated methods guide will also be subject to a public consultation.</p><p> </p><p>NICE has established a working group, consisting of members from NICE, NHS England, the Department, patient organisations and the life sciences industry. The working group reports to a steering group, chaired by NICE and with members from NHS England, the Department, and an independent academic methodologist. The steering group will present its recommendations to NICE’s Senior Management Team, which in turn will report to the NICE Board. NICE approached patient groups with experience of NICE and its processes and methods. There are three patient group representatives on the working group with a wide range of experience, covering a range of topic areas, reflecting the programmes under review. Membership of the working group will be published in due course.</p><p> </p><p>NICE is now in the process of scoping the review of the methods for technology appraisal and highly specialised technologies evaluations with input from the working group and steering group. The scope of the review - a list of the aspects of NICE’s current methods that will be considered in the review - will be presented to the NICE Board in July. Additional detail and more information will be made available on the NICE website in due course. NICE anticipates being in a position to confirm the revised methods guide by the end of 2020, following public consultation.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy remove filter
star this property grouped question UIN
263870 more like this
263872 more like this
263873 more like this
263874 more like this
star this property question first answered
remove maximum value filtermore like thismore than 2019-06-20T13:18:08.15Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4382
unstar this property label Biography information for Daniel Zeichner more like this